Welcome!

News Feed Item

Cytos Biotechnology Announces Full Year 2013 Financial Results

ZURICH, February 13, 2014 /PRNewswire/ --

Cytos Biotechnology Ltd (SIX:CYTN) today presented its full year 2013 financial results.

Full year consolidated financial figures 2013:

Balance sheet

Funds available for financing the Company's operations amount to CHF 40.00 million as per December 31, 2013, and include cash and cash equivalents, financial assets and trade and other receivables. This is CHF 11.35 million higher than on December 31, 2012 (CHF 28.65 million). This net change is composed of a cash increase of CHF 31.23 million due to funds raised in the form of equity (CHF 24.60 million) and debt (CHF 6.63 million) as well as a payment of CHF 1.00 million from a collaboration partner and other payments of CHF 0.20 million. Cash decreased by CHF 1.10 million due to share capital issuance costs as well as funds (CHF 19.98 million) mainly spent on ongoing operating activities  - in particular, the global clinical Phase 2b trial with CYT003 in allergic asthma.

As of December 31, 2013, convertible bonds with a nominal value of CHF 13.17 million are issued and outstanding, i.e. not held by the Company. These convertible bonds are due for repayment at 150% of par in February 2015 unless they are converted into equity. In 2013 the conversion price was reduced from CHF 7.71 to CHF 7.32 per share due to the anti-dilution clause. The current conversion price is subject to further reduction on certain conditions. Furthermore, convertible loan notes with a nominal value of CHF 13.25 million are issued and outstanding per December 2013. They become due for repayment in February 2015 unless they are converted into equity. In 2013 the conversion price was reduced from CHF 2.244 to CHF 2.13 per share due to the anti-dilution clause. The current conversion price is subject to further reduction on certain conditions.

Revenues

Revenues decreased from CHF 1.10 million in 2012 to CHF 1.00 million in 2013. In 2012 the revenue stemmed from license fees from Novartis of CHF 1.00 million and revenue from a technology transfer of CHF 0.10 million. In 2013 the revenue derived solely from license fees from Novartis.

Cash burn

The gross cash burn for operating activities, as calculated on the cashflow statement, increased from CHF 1.10 million in 2012 to CHF 1.68 million in 2013 on average per month.

Financial summary (IFRS, consolidated)

    (in CHF million)                             Results 2013     Results 2012
    Revenue                                               1.0              1.1
    Net operating cost                                 (24.3)           (14.6)
    Operating loss                                     (23.3)           (13.5)
    Net loss                                           (30.8)            (9.3)
    Net loss per share (in CHF)                        (1.32)           (0.57)

                                                 31.Dezember     31. Dezember
    (in CHF million)                                    2013             2012
    Cash, cash equivalents, financial assets
    & trade and other receivables                       40.0             28.7
    Full-time equivalents (number)                      28.7               21


Full year statutory financial figures 2013:

Financial summary (statutory)

    (in CHF million)                     Results 2013     Results 2012
    Revenue                                       1.0              1.1
    Total operating expenses                   (42.7)           (20.6)
    Operating loss                             (41.7)           (19.5)
    Other income                                  2.0              6.5
    Net loss                                   (44.5)           (15.7)

                                          December 31,    December 31,
    (in CHF million)                             2013             2012
    Total assets                                 47.6             54.6
    Total liabilities                            50.4             37.3
    Shareholder's equity                        (2.8)             17.3


The full financial statements can be found on http://www.cytos.com/reports-and-presentations.

Conference call on Thursday, February 13, 2014, 3 pm - 4 pm CET

Participants are kindly asked to call the following numbers 10 - 15 minutes before Conference schedule.

Participant Dial-in numbers for conference call:

+41(0)58-310-50-00 (Europe)

+44(0)203-059-58-62 (UK)

+1(1)631-570-5613 (USA)

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of targeted immuno-therapies. The Company's lead product candidate CYT003 is a novel, first-in-class, immune modulator in Phase 2 clinical development as a potential new treatment for asthma.

CYT003 has a novel mechanism of action that inhibits the immune response that causes asthma, and may therefore be beneficial for the control of asthma. In a successfully completed Phase 2a study, CYT003 was shown to maintain asthma control and lung function in patients with persistent allergic asthma, despite withdrawal of standard therapy with inhaled corticosteroids.

CYT003 has been shown to have a good safety and tolerability profile in more than 450 individuals receiving the active agent so far. Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

http://www.cytos.com

Forward Looking Statements

This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.  You are urged to consider statements that include the words "will" or "expect" or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, including that CYT003 may not demonstrate safety or efficacy in clinical trials, that there may be delays in development or that CYT003 may not receive marketing approval, and that the Company relies on outside financing to meet capital requirements, which may not be available under acceptable terms or at all. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

For further information, please contact:
Cytos Biotechnology Ltd
Harry Welten
Chief Financial Officer
Tel: +41(0)44-733-46-46
e-mail: [email protected]

US Investor enquiries
Susan A. Noonan
Tel: +1(212)966-3650
e-mail: [email protected]

SOURCE Cytos Biotechnology

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
Struggling to keep up with increasing application demand? Learn how Platform as a Service (PaaS) can streamline application development processes and make resource management easy.
Much of the value of DevOps comes from a (renewed) focus on measurement, sharing, and continuous feedback loops. In increasingly complex DevOps workflows and environments, and especially in larger, regulated, or more crystallized organizations, these core concepts become even more critical. In his session at @DevOpsSummit at 18th Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, will show how, by focusing on 'metrics that matter,' you can provide objective, transparent, and meaningfu...
If there is anything we have learned by now, is that every business paves their own unique path for releasing software- every pipeline, implementation and practices are a bit different, and DevOps comes in all shapes and sizes. Software delivery practices are often comprised of set of several complementing (or even competing) methodologies – such as leveraging Agile, DevOps and even a mix of ITIL, to create the combination that’s most suitable for your organization and that maximize your busines...
In his session at @ThingsExpo, Chris Klein, CEO and Co-founder of Rachio, will discuss next generation communities that are using IoT to create more sustainable, intelligent communities. One example is Sterling Ranch, a 10,000 home development that – with the help of Siemens – will integrate IoT technology into the community to provide residents with energy and water savings as well as intelligent security. Everything from stop lights to sprinkler systems to building infrastructures will run ef...
SYS-CON Events announced today that Peak 10, Inc., a national IT infrastructure and cloud services provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Peak 10 provides reliable, tailored data center and network services, cloud and managed services. Its solutions are designed to scale and adapt to customers’ changing business needs, enabling them to lower costs, improve performance and focus inter...
In the world of DevOps there are ‘known good practices’ – aka ‘patterns’ – and ‘known bad practices’ – aka ‘anti-patterns.' Many of these patterns and anti-patterns have been developed from real world experience, especially by the early adopters of DevOps theory; but many are more feasible in theory than in practice, especially for more recent entrants to the DevOps scene. In this power panel at @DevOpsSummit at 18th Cloud Expo, moderated by DevOps Conference Chair Andi Mann, panelists will dis...
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
Artificial Intelligence has the potential to massively disrupt IoT. In his session at 18th Cloud Expo, AJ Abdallat, CEO of Beyond AI, will discuss what the five main drivers are in Artificial Intelligence that could shape the future of the Internet of Things. AJ Abdallat is CEO of Beyond AI. He has over 20 years of management experience in the fields of artificial intelligence, sensors, instruments, devices and software for telecommunications, life sciences, environmental monitoring, process...
Increasing IoT connectivity is forcing enterprises to find elegant solutions to organize and visualize all incoming data from these connected devices with re-configurable dashboard widgets to effectively allow rapid decision-making for everything from immediate actions in tactical situations to strategic analysis and reporting. In his session at 18th Cloud Expo, Shikhir Singh, Senior Developer Relations Manager at Sencha, will discuss how to create HTML5 dashboards that interact with IoT devic...
See storage differently! Storage performance problems have only gotten worse and harder to solve as applications have become largely virtualized and moved to a cloud-based infrastructure. Storage performance in a virtualized environment is not just about IOPS, it is about how well that potential performance is guaranteed to individual VMs for these apps as the number of VMs keep going up real time. In his session at 18th Cloud Expo, Dhiraj Sehgal, in product and marketing at Tintri, will discu...
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, will provide tips on how to be successful in large scale machine lear...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
The IoTs will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, will demonstrate how to move beyond today's coding paradigm and share the must-have mindsets for removing complexity from the development proc...
SYS-CON Events announced today that Ericsson has been named “Gold Sponsor” of SYS-CON's @ThingsExpo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. Ericsson is a world leader in the rapidly changing environment of communications technology – providing equipment, software and services to enable transformation through mobility. Some 40 percent of global mobile traffic runs through networks we have supplied. More than 1 billion subscribers around the world re...